This is a short conversational excerpt from a May 5, 2025 YouTube video titled "Weight Loss Drugs: Short-Term Gain, Long-Term Risk?" featuring Robert Whitfield MD. In this excerpt the speakers argue that recent weight-loss drugs strongly modify eating behavior, drove rapid commercial uptake (including insurance coverage), created large profits at the expense of potential long-term harms, and prompted debate over peptides, market monopolies, and the need for more regulation.
Well, it's like they, they went for the short term win instead of the long term one. Right. You got a lifelong patient with dialysis, or you get the money quick now. And it became the number one drug and sold in the world. Right.
Because for your audience, what these drugs do is they modify behavior. No drug in history has done it this effectively. You take that drug, you don't even care about eating. So the amount of people in the line at Whataburger in Texas or McDonald's in Scottsdale has gone way down.
And you can get it through insurance.
Yes. Right. So I, I 100. They're just kicking themselves in board meetings all the time.
They're like, well, that's okay. They can just handle it. Like, they handle peptides and just take them off the market and go, wait a minute.
That's why we.
Need more regulation.
It's not been pulled. Like, to me, you know, the peptide thing's a joke. Like, peptides have been around forever, ever. So, like, okay, you, you found something that you want to mess with, so now you got to pull it. That's. Say it's like stem cell therapy. Like, there's nothing super complicated about this. You, you can make it sound super complicated and, and make it a patient safety issue or make us think you're making it a patient safety issue, which is not. It's more of a money issue. You want to monopolize.
Yeah.
And control that particular therapy.
Yeah.
That you can, you can benefit from. I get it. We're not like.
